1way: Difference between revisions

Revision as of 14:04, 29 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:1way.png

Template:STRUCTURE 1way

ACTIVE SITE THROMBIN INHIBITORSACTIVE SITE THROMBIN INHIBITORS

Template:ABSTRACT PUBMED 15658854

About this StructureAbout this Structure

1WAY is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

Fragment-based lead discovery using X-ray crystallography., Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H, J Med Chem. 2005 Jan 27;48(2):403-13. PMID:15658854

Page seeded by OCA on Tue Jul 29 14:04:55 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:1way.gif|left|200px]]
+{{Seed}}
+[[Image:1way.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_1way|  PDB=1way  |  SCENE=  }}
-'''ACTIVE SITE THROMBIN INHIBITORS'''
+===ACTIVE SITE THROMBIN INHIBITORS===
-==Overview==
+<!--
-Fragment screening offers an alternative to traditional screening for discovering new leads in drug discovery programs. This paper describes a fragment screening methodology based on high throughput X-ray crystallography. The method is illustrated against five proteins (p38 MAP kinase, CDK2, thrombin, ribonuclease A, and PTP1B). The fragments identified have weak potency (&gt;100 microM) but are efficient binders relative to their size and may therefore represent suitable starting points for evolution to good quality lead compounds. The examples illustrate that a range of molecular interactions (i.e., lipophilic, charge-charge, neutral hydrogen bonds) can drive fragment binding and also that fragments can induce protein movement. We believe that the method has great potential for the discovery of novel lead compounds against a range of targets, and the companion paper illustrates how lead compounds have been identified for p38 MAP kinase starting from fragments such as those described in this paper.
+The line below this paragraph, {{ABSTRACT_PUBMED_15658854}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 15658854 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_15658854}}
 ==About this Structure==
@@ Line 43: / Line 47: @@
 [[Category: Serine protease]]
 [[Category: Vitamin k]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 13:24:02 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 14:04:55 2008''